Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team
Analyst Comment

Aiforia's collaboration with Paris Hospital District moves forward

Aiforia Technologies

Translation: Original comment published in Finnish on 9/5/2024 at 12:13 noon EEST.

The start of the collaboration was announced earlier this spring, so the press release comes as no surprise, although the agreement announced now provides a concrete indication of the first steps of the collaboration. According to the release, the collaboration at this stage includes the use of Aiforia's AI solutions in the analysis of tissue samples from prostate cancer patients and the use of Aiforia's AI model development software. Aiforia will be deployed at the pathology department of the Bicetre Hospital (AP-HP Paris Saclay University), which has been a pilot site for digital pathology in France since 2018.

The clinical use of Aiforia in Paris will start on a somewhat smaller scale (1/5 of the current CE-marked AI models), so revenue streams from the customer are expected to be slow. The contract partner, Assistance Publique–Hôpitaux de Paris (AP-HP), is a university hospital group with 38 hospitals in the Paris region, serving 8 million patients per year. Thus, the potential for expansion in this hospital group alone is significant. In addition, Aiforia will be able to demonstrate its product capabilities directly at the heart of the digitization of French pathology and is well positioned to take a significant market share in France, making the collaboration strategically valuable in the longer term. Our forecasts have already included this account and require Aiforia to continue to deliver new customer wins and customer deployment progress, so the release has no impact on our forecasts or our view of the company.

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Read more on company page

Key Estimate Figures2024-08-29

202324e25e
Revenue2.43.45.8
growth-%49.3 %41.2 %71.1 %
EBIT (adj.)-12.9-12.1-11.8
EBIT-% (adj.)-537.1 %-358.4 %-204.4 %
EPS (adj.)-0.50-0.42-0.41
Dividend0.000.000.00
Dividend %
P/E (adj.)neg.neg.neg.
EV/EBITDAneg.neg.neg.

Forum discussions

This also restricts issues in January. Persons discharging managerial responsibilities at the issuer are subject to a 30-day closed period before...
yesterday
by Zen65
1
Will that ownership list be updated before trading begins with these new shares on the 15th, or will it only be visible at the beginning of ...
yesterday
by Salvelinus
0
Someone said it would have been better to wait until January with the offering, perhaps for the sake of the share price, but has anyone ever...
yesterday
by Zen65
0
Aiforia Technologies Plc – Manager’s transactions – Tuomas Tenkanen Aiforia Technologies Plc TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL ...
yesterday
by Uuno
6
It seems the offering didn’t sell very well, as Tenkanen ended up with more shares than his original commitment: TJT Technologies Oy, a company...
yesterday
5
This probably does meet the characteristics of a crisis company, when a directed share issue is discussed. Otherwise, next year they would have...
12/11/2025, 2:00 PM
by Zen65
0
Based on the tone of your text, you seem agitated, so now would be a good time to breathe in and out and calm down a bit, so that the constructive...
12/11/2025, 11:50 AM
by Pohjolan Eka
28
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.